Literature DB >> 28631086

Nearly a Third of High-Grade Dysplasia and Colorectal Cancer Is Undetected in Patients with Inflammatory Bowel Disease.

Swathi Eluri1,2, Alyssa M Parian3, Berkeley N Limketkai4,5, Christina Y Ha6,7, Steven R Brant3, Sharon Dudley-Brown3, Jonathan E Efron3, Sandy G Fang3, Susan L Gearhart3, Michael R Marohn3, Stephen J Meltzer3, Safar Bashar3, Brindusa Truta3, Elizabeth A Montgomery3, Mark G Lazarev3.   

Abstract

BACKGROUND: It is unclear whether intensive surveillance protocols have resulted in a decreased incidence of colorectal cancer (CRC) in inflammatory bowel disease (IBD). AIMS: To determine the prevalence and characteristics of IBD associated high-grade dysplasia (HGD) or CRC that was undetected on prior colonoscopy.
METHODS: This is a single-center, retrospective study from 1994 to 2013. All participants had a confirmed IBD diagnosis and underwent a colectomy with either HGD or CRC found in the colectomy specimen.The undetected group had no HGD or CRC on prior colonoscopies. The detected group had HGD or CRC identified on previous biopsies.
RESULTS: Of 70 participants, with ulcerative colitis (UC) (n = 47), Crohn's disease (CD) (n = 21), and indeterminate colitis (n = 2), 29% (n = 20) had undetected HGD/CRC at colectomy (15 HGD and 5 CRC). In the undetected group, 75% had prior LGD, 15% had indefinite dysplasia, and 10% had no dysplasia (HGD was found in colonic strictures). Patients in the undetected group were more likely to have pancolitis (55 vs. 20%) and multifocal dysplasia (35 vs. 8%). The undetected group was less likely to have CRC at colectomy (25 vs. 62%). There was a trend toward right-sided HGD/CRC at colectomy (40 vs. 20%; p = 0.08). In addition, 84% of the lesions found in the rectum at colectomy were not seen on prior colonoscopy in the undetected group.
CONCLUSIONS: The prevalence of previously undetected HGD/CRC in IBD found at colectomy was 29%. The high proportion of undetected rectal and right-sided HGD/CRC suggests that these areas may need greater attention during surveillance.

Entities:  

Keywords:  Cancer screening; Colonoscopy; Colorectal neoplasms; Inflammatory bowel diseases

Mesh:

Year:  2017        PMID: 28631086      PMCID: PMC6435268          DOI: 10.1007/s10620-017-4652-5

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  21 in total

Review 1.  Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002).

Authors:  Stuart R Cairns; John H Scholefield; Robert J Steele; Malcolm G Dunlop; Huw J W Thomas; Gareth D Evans; Jayne A Eaden; Matthew D Rutter; Wendy P Atkin; Brian P Saunders; Anneke Lucassen; Paul Jenkins; Peter D Fairclough; Christopher R J Woodhouse
Journal:  Gut       Date:  2010-05       Impact factor: 23.059

2.  Challenges in calculating the risk for colorectal cancer in patients with ulcerative colitis.

Authors:  Peter L Lakatos; Laszlo Lakatos
Journal:  Clin Gastroenterol Hepatol       Date:  2012-05-18       Impact factor: 11.382

3.  Protective association of colonoscopy against proximal and distal colon cancer and patterns in interval cancer.

Authors:  Amandeep K Shergill; Erin E Conners; Kenneth R McQuaid; Sara Epstein; James C Ryan; Janak N Shah; John Inadomi; Ma Somsouk
Journal:  Gastrointest Endosc       Date:  2015-05-01       Impact factor: 9.427

4.  Surveillance of IBD Using High Definition Colonoscopes Does Not Miss Adenocarcinoma in Patients with Low-grade Dysplasia.

Authors:  Noa Krugliak Cleveland; Ruben J Colman; Dylan Rodriquez; Ayal Hirsch; Russell D Cohen; Stephen B Hanauer; John Hart; David T Rubin
Journal:  Inflamm Bowel Dis       Date:  2016-03       Impact factor: 5.325

Review 5.  AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease.

Authors:  Francis A Farraye; Robert D Odze; Jayne Eaden; Steven H Itzkowitz
Journal:  Gastroenterology       Date:  2010-02       Impact factor: 22.682

6.  Rate of early/missed colorectal cancers after colonoscopy in older patients with or without inflammatory bowel disease in the United States.

Authors:  Yize R Wang; John R Cangemi; Edward V Loftus; Michael F Picco
Journal:  Am J Gastroenterol       Date:  2013-01-08       Impact factor: 10.864

7.  The risk of colorectal cancer in ulcerative colitis: a meta-analysis.

Authors:  J A Eaden; K R Abrams; J F Mayberry
Journal:  Gut       Date:  2001-04       Impact factor: 23.059

8.  Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years.

Authors:  Tine Jess; Jacob Simonsen; Kristian Tore Jørgensen; Bo Vestergaard Pedersen; Nete Munk Nielsen; Morten Frisch
Journal:  Gastroenterology       Date:  2012-04-19       Impact factor: 22.682

9.  Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis.

Authors:  Matthew D Rutter; Brian P Saunders; Kay H Wilkinson; Steve Rumbles; Gillian Schofield; Michael A Kamm; Christopher B Williams; Ashley B Price; Ian C Talbot; Alastair Forbes
Journal:  Gastroenterology       Date:  2006-04       Impact factor: 22.682

10.  Association of colonoscopy and death from colorectal cancer.

Authors:  Nancy N Baxter; Meredith A Goldwasser; Lawrence F Paszat; Refik Saskin; David R Urbach; Linda Rabeneck
Journal:  Ann Intern Med       Date:  2008-12-15       Impact factor: 25.391

View more
  8 in total

1.  Getting a Low Grade for Missing High-Grade Dysplasia and Colorectal Cancer in IBD.

Authors:  James R Conner; Robert H Riddell
Journal:  Dig Dis Sci       Date:  2017-10-20       Impact factor: 3.199

2.  Differential role of chronic liver diseases on the incidence of cancer: a longitudinal analysis among 248,224 outpatients in Germany.

Authors:  Sven H Loosen; David Schöler; Mark Luedde; Johannes Eschrich; Tom Luedde; Karel Kostev; Christoph Roderburg
Journal:  J Cancer Res Clin Oncol       Date:  2022-07-22       Impact factor: 4.322

3.  Possible Earlier Diagnosis of Ulcerative Colitis-Associated Neoplasia: A Retrospective Analysis of Interval Cases during Surveillance.

Authors:  Takashi Hisabe; Toshiyuki Matsui; Kazutomo Yamasaki; Tsuyoshi Morokuma; Kenmei Aomi; Naoyuki Yoshizawa; Noritaka Takatsu; Kenshi Yao; Toshiharu Ueki; Kitaro Futami; Hiroshi Tanabe; Akinori Iwashita
Journal:  J Clin Med       Date:  2021-04-29       Impact factor: 4.241

Review 4.  Surveillance for colorectal cancer and chemoprevention in ulcerative and Crohn's colitis: The need for clinical strategies to increase effectiveness.

Authors:  Affifa Farrukh; John F Mayberry
Journal:  JGH Open       Date:  2019-04-11

Review 5.  Organometallic Compounds and Metal Complexes in Current and Future Treatments of Inflammatory Bowel Disease and Colorectal Cancer-a Critical Review.

Authors:  Adrian Szczepaniak; Jakub Fichna
Journal:  Biomolecules       Date:  2019-08-22

Review 6.  Colorectal carcinoma in the course of inflammatory bowel diseases.

Authors:  Andrzej Hnatyszyn; Szymon Hryhorowicz; Marta Kaczmarek-Ryś; Emilia Lis; Ryszard Słomski; Rodney J Scott; Andrzej Pławski
Journal:  Hered Cancer Clin Pract       Date:  2019-07-12       Impact factor: 2.857

Review 7.  Systemic Interleukins' Profile in Early and Advanced Colorectal Cancer.

Authors:  Paulina Czajka-Francuz; Sylwia Cisoń-Jurek; Aleksander Czajka; Maciej Kozaczka; Jerzy Wojnar; Jerzy Chudek; Tomasz Francuz
Journal:  Int J Mol Sci       Date:  2021-12-23       Impact factor: 5.923

8.  Sustained Resolution of Multifocal Low-Grade Dysplasia in Ulcerative Colitis.

Authors:  Andrew Canakis; Peter Dellatore; Matthew Josephson; Justin Canakis; Zainab Alruwaii; Mark Lazarev; Steven R Brant
Journal:  ACG Case Rep J       Date:  2019-08-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.